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Abstract. In a previous genome‑wide expression profiling study, 
we identified E2F2 as a hyperexpressed gene in stem‑like cells 
of distinct glioblastoma multiforme (GBM) specimens. Since 
the encoded E2F2 transcription factor has been implicated in 
both tumor suppression and tumor development, we conducted a 
functional study to investigate the pertinence of E2F2 to human 
gliomagenesis. E2F2 expression was knocked down by trans-
fecting U87MG cells with plasmids carrying a specific silencing 
shRNA. Upon E2F2 silencing, in vitro cell proliferation was 
significantly reduced, as indicated by a time‑course analysis of 
viable tumor cells. Anchorage‑independent cell growth was also 
significantly inhibited after E2F2 silencing, based on cell colony 
formation in soft agar. Subcutaneous and orthotopic xenograft 
models of GBM in nude mice also indicated inhibition of tumor 
development in vivo, following E2F2 silencing. As expression 
of the E2F2 gene is associated with glioblastoma stem cells 
and is involved in the transformation of human astrocytes, the 
present findings suggest that E2F2 is involved in gliomagenesis 
and could be explored as a potential therapeutic target in malig-
nant gliomas.
Introduction
Glioblastoma multiforme (GBM) is the most frequent, aggres-
sive and lethal primary malignant tumor of the central nervous 
system in adults worldwide. No effective treatment for this highly 
aggressive and infiltrative tumor is available, and the median 
survival time is <16 months following initial diagnosis, with 
a five‑year survival rate as low as 4.7% (1,2). High proportion 
of mitotically active cells displaying pleomorphic morphology, 
pseudopalisading necrosis associated with microvascular hyper-
plasia, and infiltrative cell growth towards the parenchyma are 
some of the main histopathological features of GBM. Such key 
features that are observed in the majority of GBM specimens 
can be recapitulated in orthotopic xenograft models by the 
intracerebral injection of patient‑derived stem‑like cells, which 
are considered to be responsible for gliomagenesis (3). 
A previous genome‑wide expression profiling study iden-
tified E2F2 as a hyperexpressed gene in CD133+ stem‑like 
cells isolated from fresh GBM specimens. Furthermore, the 
frequency and levels of E2F2 expression correlated significantly 
with the malignancy of astrocytomas, being predominantly 
hyperexpressed in GBM (4). The E2F2 protein belongs to a 
large family of transcription factors regulating cell proliferation, 
cell division and cell differentiation. The E2F family has nine 
members, which have been divided into two subclasses (activa-
tors and repressors) based on their transcriptional properties 
and conserved structural features. E2F2 has a strong transcrip-
tional activation domain and is able to interact with the tumor 
suppressor Rb (5). The Rb/E2F network regulates the expression 
of genes involved in cell cycle progression, DNA replication, 
checkpoint control, apoptosis, differentiation, DNA damage 
repair and development (6). Despite its well‑known positive 
regulation of cell proliferation, the contribution of E2F2 to 
tumorigenesis is not so clear, since it has been reported to exert 
either pro‑oncogenic or tumor suppression effects (7). 
Since CD133+ GBM cells have originally been reported to 
have increased tumor initiating capability in vivo (3,8), a func-
tional study was carried out to address the relevance of E2F2 
to the tumorigenic properties of GBM, and its value as a thera-
peutic target for treatment of this highly aggressive brain tumor.
Materials and methods
Cell culture. The human glioblastoma cell line U87MG was 
kindly provided by Dr Suely K. N. Marie from the Laboratory 
of Medical Investigation (LIM15) at the University of São Paulo 
(São Paulo, Brazil). Cells were grown in Dulbecco's modified 
Eagle's Medium‑low glucose (DMEM‑LG; Invitrogen Life 
Technologies, Carlsbad, CA, USA) supplemented with 2 mM 
L‑glutamine, 10% fetal bovine serum (FBS), 100 U/ml peni-
cillin and 100 µg/ml streptomycin (all Life Technologies, Grand 
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Island, NY, USA), in a humidified atmosphere at 37˚C with 
5% CO2. 
Transient E2F2 silencing. U87MG cells were transfected 
with Sure Silencing™ shRNA plasmids (Super Array, 
SABiosciences, Frederick, MD, USA) designed to specifi-
cally knock down the expression of the E2F2 gene. After 24 h 
without FBS for synchronization, U87MG cells were seeded in 
six‑well plates at a density of 105 cells per well and incubated 
for 24 h. Cells were then transfected with non‑specific DNA 
(negative, non‑specific control; NS) or shRNA silencing E2F2 
(shE2F2) (both SABiosciences, Frederick, MD, USA), using 
Lipofectamine™ RNAiMAX (Life Technologies) according to 
the manufacturer's instructions. The total plasmid concentration 
in each well was 0.5 µg. Positive control cells were treated with 
Lipofectamine RNAiMAX, identically to the other experi-
mental groups, but received no plasmids. Twenty‑four and 72 h 
after transfection, the glioblastoma cells displaying neomycin 
resistance were selected in medium containing 500 µg/ml G418 
(Life Technologies) and harvested after 96 h of culture for 
in vitro and in vivo experiments.
Quantification of gene expression by quantitative polymerase 
chain reaction (qPCR). Total RNA was extracted using an 
RNeasy® mini kit (50) (Qiagen GmbH, Hilden, Germany), 
according to the manufacturer's instructions, and quantified by 
measuring the absorbance at 260 nm (NanoDrop 2000 spectro-
photometer, Thermo Fisher Scientific, Wilmington, DE, USA). 
The reverse transcription (RT) reaction was performed using 
1 µg of total RNA with Superscript™ III Reverse Transcriptase 
enzyme (Life Technologies). Real‑time RT‑PCR was performed 
in a 7500 Real‑time RT‑PCR system (Life Technologies), by the 
SYBR® GreenER™ incorporation method (Power SYBR Green 
PCR Master Mix; Life Technologies). The cycling conditions 
were as follows: 95˚C for 15 sec, followed by 50 cycles at 60˚C 
for 30 sec, 95˚C for 1 h and 55˚C for 30 sec. All primer pairs were 
designed in different exons using Primer3 Input version 0.4.0 
(http://gmdd.shgmo.org/primer3/?seqid=47), and synthesized by 
Promega Corporation (Madison, WI, USA). The primer sequences 
were as follows: Forward, 5'‑GGACAGGAATGGCCTC‑3' 
and reverse, 5'‑GTCCTTCGAGGAGCTC‑3' for E2F2; 
and forward, 5'‑GGACAGGAATGGCCTC‑3' and reverse, 
5'‑GTCCTTCGAGGAGCTC‑3' for GAPDH.
Cell proliferation assays. U87MG cells were seeded on 96‑well 
plates at an initial density of 5x104 cells/well, and proliferation 
was measured 24, 48 and 72 h after plating by direct counting 
of viable cells in a Neubauer chamber with Trypan blue (1:1; 
Sigma‑Aldrich, St. Louis, MO, USA). The number of viable cells 
was also assessed by the 3‑(4, 5‑dimethylthiazolyl‑2)‑2, 5‑diphe-
nyltetrazolium bromide (MTT) assay, adding 10 µl of MTT to 
the cell preparation and incubating for 2 h in a humidified atmo-
sphere at 37˚C with 5% CO2. Cells were lysed in 100 µl of 100% 
dimethylsulfoxide and absorbance was detected at 550 nm using 
a 96‑well plate reader (iMark Microplate Absorbance Reader; 
Bio‑Rad, Hercules, CA, USA). Each sample was run in tripli-
cate. Anchorage‑independent cell growth was also assessed 
by the soft agar assay. Briefly, 2 ml of 0.5% agar was added to 
each well of a 12‑well plate. Detached U87MG cells were mixed 
with an agarose suspension (0.3% final concentration), and then 
layered onto the 0.5% agarose underlay. Culture medium was 
changed every three days, and the number of cell foci ≥100 mm 
in diameter was counted after 21 days using the EVOS® XL 
cell imaging system (Life Technologies). Each experiment was 
performed in triplicate.
In vivo tumorigenesis
Subcutaneous xenograft model. U87MG glioblastoma cells 
(106 cells/mouse) were suspended in DMEM‑LG, injected 
subcutaneously into the right flank of BALB/c nude mice 
(male; 4‑8 weeks old) obtained from the University of São 
Paulo, and allowed to grow for 50 days or until the tumor 
reached a volume of 2,500 mm3 (tumor weight, 100‑200 mg). 
Animals (n=5 per group) were monitored daily and tumors 
were measured with a digital caliper rule twice a week. Tumor 
volume was estimated using the formula: Volume = (minor 
diameter2 x major diameter)/2.
Orthotopic glioblastoma xenograft model. Adult BALB/c 
nude mice (~20 g) were anesthetized by intraperitoneal 
administration of ketamine (100 mg/kg)/xylazine (15 mg/kg) 
(both Syntec Brasil, Cotia, Brazil). Following sedation, mice 
were positioned in a stereotaxic frame. The scalp was steril-
ized with iodine and 70% ethanol and a median incision of 
~1.0 cm was made. The cranial cavity was assessed by a right 
frontal hole using an electric mini‑drill (Micromotor LB100; 
Beltec, Araraquara, Brazil). A total of 106 U87MG cells (E2F2 
Figure 1. (A) Effects of E2F2 knockdown on glioblastoma cell proliferation. 
E2F2 silencing levels 96 h post‑transfection of U87MG cells. Total number 
of viable tumor cells after 24, 48, 72 and 96 h of cell culture accessed by 
(B) direct cell counting or (C) 3‑(4, 5‑dimethylthiazolyl‑2)‑2, 5‑diphenyltet-
razolium bromide assay. Control, treated with Lipofectamine™ only; NS, 
non‑specific control; shE2F2, E2F2 knockdown. *P<0.05.
  A
  B
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knocked down and control) were suspended in 5 µl of DMEM 
low glucose without FBS and inoculated with a high‑precision 
microsyringe (701RN; Hamilton Company, Reno, NV, USA) 
into the striatum, 0.9 mm in front of the bregma, 2.5 mm later-
ally to the right and 3.0 mm ventrally, at a 0.5 µl/min rate. At 
the end of cell injection, the needle was retained in the incision 
for 5 min and slowly removed to prevent the cell suspension 
from flowing back. The scalp was closed with 2‑0 silk suture 
and the animals were housed under standard controlled condi-
tions (7:00am to 7:00pm light/dark cycle; 20‑22˚C; 45‑55% 
humidity) with food and water ad libitum. Histological analysis 
was performed 30 days post‑intracranial implantation of tumor 
cells. All efforts were made to minimize animal suffering as 
proposed by the International Ethical Guideline for Biomedical 
Research (CIOMS/OMS, 1985). The study was approved by the 
ethics committee for animal research of the University of São 
Paulo (CEUA protocol no. 132/2011). 
Histological analysis. Brain samples were frozen in cold 
isopentane solution (Sigma‑Aldrich) at ‑25˚C, and then sectioned 
at 20 µm on a cryostat. Coronal histological sections of the tumor 
xenograft and surrounding brain area were mounted on silanized 
microscope slides (StarFrost®, Knittel‑Gläser, Braunschweig, 
Germany), and stained with hematoxylin and eosin. Microscope 
images were captured by an ExwaveHAD Color video digital 
camera (Sony Corporation, Tokyo, Japan) attached to a Nikon 
Eclipse E600 microscope (Nikon, Corporation, Tokyo, Japan), 
using the WinAVI Video Capture software (WinAVI, Eden 
Prairie, MN, USA).
Statistical Analysis. All experiments were performed in tripli-
cate and three independent experiments were performed. Data 
were analyzed by one way analysis of variance with Bonferroni 
as the post hoc test, using GraphPad Prism 3.0 (GraphPad 
Software, San Diego, CA, USA). P<0.05 was considered to 
indicate a statistically significant difference. Data are presented 
as the mean ± standard deviation.
Results
E2F2 knockdown inhibits glioblastoma cell proliferation 
in vitro. Specific knockdown of E2F2 expression was previously 
confirmed in U87MG cells, reaching a silencing level of ~60% 
after 96 h of transfection with shRNA. Under standard growth 
conditions in vitro, the total number of viable tumor cells was 
significantly lower after 48, 72 and 96 h of E2F2 knockdown 
compared with that in the NS control group (P=0.0044, P=0.0007 
and P=0.0035, respectively). Similar results were observed by 
the MTT assay, based on the activity of mitochondrial succinate 
Figure 2. Effects of E2F2 knockdown on glioblastoma anchorage‑independent cell growth. Tumor cells were grown in soft agar medium and cell colonies 
counted after 21 days. (A) Total amount of colonies and (B) colonies ≥100 µm only were plotted. (C) Demonstrative images of tumor cell colonies at 5x and 
10x magnification. Control, treated with Lipofectamine™ only; NS, non‑specific control; shE2F2, E2F2 knockdown. *P<0.05.
  A   B
  C
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dehydrogenase, which indicated significantly lower numbers 
of viable tumor cells after 72 h and 96 h of E2F2 knockdown, 
compared with the controls (P<0.0001 for the two time points) 
(Fig. 1). The absorbance levels acquired from cells subjected to 
E2F2 knockdown were virtually unchanged over the time course 
examined (24‑96 h), suggesting inhibition of cell proliferation.
Anchorage‑independent cell growth is a valuable indicator 
of tumorigenic capability, since it is associated with neoplastic 
transformation and metastatic potential. In agreement with the 
previous cell viability experiments, the efficiency of U87MG 
cells to generate tumor cell colonies by anchorage‑independent 
growth in a semi‑solid medium was significantly reduced 
by knocking down E2F2. Both the total amount of colonies 
(≥100 µm) and the average size of the colonies were signifi-
cantly lower when assaying U87MG cells subjected to E2F2 
knockdown, compared with those of the control cells (P=0.0081 
and P=0.0076, respectively) (Fig. 2). 
E2F2 knockdown inhibits gliomagenesis in xenograft models. 
In order to test whether E2F2 knockdown would affect in vivo 
tumorigenesis, two xenograft models of human GBM were 
employed. Tumors derived from the subcutaneous injection of 
U87MG cells in nude mice were measurable ~30 days following 
injection, reaching volumes usually higher than 1,000 mm3 in 
the subsequent 20 days of in vivo growth. In a period of 50 days 
post‑cell injection, although transient, the E2F2 knockdown in 
U87MG cells inhibited tumor development. Tumors generated 
from U87MG cells with E2F2 knockdown were smaller and 
significantly lighter than tumors resulting from control cells 
(P=0.04) (Fig. 3A). Mice bearing orthotopic U87MG tumors 
also revealed differences in brain tumor development due to 
E2F2 knockdown. In agreement with the previous subcutaneous 
xenograft model, brain tumors derived from the stereotaxic 
intracerebral injection of U87MG cells with E2F2 knockdown 
were somewhat smaller than tumors derived from control cells, 
30 days following injection in nude mice (Fig. 3B).
Discussion
Despite the conserved functions in cell cycle regulation, devel-
opment and tissue maintenance, E2F transcription factors may 
affect tumorigenic processes in different ways due to the fact 
that each member displays individual mechanisms of action and 
may control the expression of other family members through a 
complex feedback regulation (9). The function of E2F2 is less 
characterized relative to other members of the E2F family, and 
its involvement in tumorigenesis remains a matter of debate, 
since evidence of both tumor suppression and pro‑oncogenic 
activities have been reported (5). 
It has been shown in mice that deficiency in E2F2 caused by 
gene targeting (E2F2-/-) significantly increased the population 
of self‑reactive peripheral T cells, causing symptoms similar 
to severe autoimmunity. Such increment in self‑reactive T cells 
was demonstrated to be due to increased cell proliferation rates 
without evidence of differential resistance to apoptosis (10). 
More recently, however, overexpression of E2F2 was reported 
to induce p53‑mediated apoptosis of mouse retina neurons 
lacking Rb and p107, independent of other activating E2Fs (11). 
In a conditional bitransgenic mouse model of Myc‑induced 
T‑cell lymphomagenesis, Opavsky et al (12) demonstrated that 
inactivation of E2F2 (either E2F2+/- or E2F2-/-), but not of E2F1 
or E2F3, significantly accelerated tumor onset and progression, 
indicating an haploinsufficient tumor suppressor function for 
E2F2 in T cells. Similar results were obtained with MMTV‑Myc 
Figure 3. Effects of E2F2 knockdown on tumor development. (A) Average weight of tumors derived from the subcutaneous injection of U87MG cells (106 
cells/mouse) and (B) representative image of resected tumors. (C) Coronal brain section of adult BALB/c nude mice bearing intracerebral tumors resulting 
from the stereotaxic injection of U87MG cells (106 cells/brain) into the right striatum. NS: non‑specific control; shE2F2 (E2F2 knockdown). *P<0.05.
  A   B
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transgenic mice, in which E2F2 knockout delayed latency and 
reduced the incidence of Myc‑driven mammary tumors (13). 
By contrast, in neuroblastomas, E2F2 was shown to 
positively regulate MYCN transcription and thought to be 
required for full activity of MYCN expression in aggressive 
neuroblastomas usually associated with poor prognosis (14). 
Stable overexpression of E2F2 in fibroblasts indeed revealed a 
strong oncogenic capacity for this E2F member (15). Transgenic 
mice have also supported a pro‑oncogenic role for E2F2. In an 
Eµ‑pp‑E2F2 mouse model, overexpression of E2F2 induced 
mild hyperplasia of the thymus in young mice and subsequent 
development of thymomas (16). Notably, overexpression of 
E2F2 was predominantly found in cortical thymic epithelial 
cells, which are highly proliferative cells involved in T‑cell 
development and regeneration capacity of the thymus (17). In 
E2F2 knockout mice, loss of this transcription factor resulted in 
cell cycle arrest in hematopoietic progenitors (18) and increased 
DNA double‑strand breaks in erythroblasts (19).
Regarding human cancers, in addition to the abovementioned 
study in neuroblastomas, E2F2 has been shown to be under 
control of the AP‑1 transcription factor in breast cancer cells, 
where it positively regulates cell proliferation (20). Accordingly, 
high E2F2 expression was recently reported to be associated 
with poor survival of breast cancer patients (21). In prostate 
cancer cells, E2F2 expression was reported to be inhibited by 
let‑7a (22) and miR‑31 (23) microRNAs, resulting in suppression 
of tumorigenesis in a nude mice ectopic xenograft model. 
In GBM, E2F2 was identified as one of the hyper‑expressed 
genes in CD133+ tumor cells, compared with their counterparts, 
and its expression correlated with malignancy grade (4). Such 
subcellular population of GBM had been reported to have 
neural stem cells characteristics and enhanced in vivo tumor 
initiation capability (8). Studies also isolated and characterized 
CD133+ stem‑like cells in different GBM cell lines, including 
U87MG (24), establishing a useful experimental model to study 
cancer stem cell biology. 
The effects of E2F2 knockdown in U87MG cells veri-
fied in the present study by in vitro and in vivo models of 
tumorigenesis are consistent with a pro‑tumorigenic activity 
of E2F2 in GBM. In agreement with this notion, a recent 
study demonstrated that overexpression of the microRNA 
miR‑125b inhibits proliferation of CD133+ GBM cells in vitro, 
by targeting E2F2 transcripts, and that such effect on in vitro 
proliferation is rescued by overexpression of E2F2 (25). 
Overall, these concordant findings suggest that E2F2 is an 
important transcription factor regulating the tumor‑initiating 
capability of human GBM cells. Inhibitors of E2F2 expression 
may therefore be considered as candidates for drug develop-
ment to locally treat GBM, a highly malignant and devastating 
tumor of the central nervous system.
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